Piper Sandler Downgrades CommVault Systems to Neutral, Lowers Price Target to $69
Piper Sandler analyst James Fish downgrades CommVault Systems (NASDAQ:CVLT) from Overweight to Neutral and lowers the price target from $78 to $69.
Atlantic Equities Maintains Overweight on Merck & Co, Raises Price Target to $110
Atlantic Equities analyst Steve Chesney maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $105 to $110.
SVB Leerink Upgrades BioNTech to Outperform, Lowers Price Target to $223
SVB Leerink analyst Daina Graybosch upgrades BioNTech (NASDAQ:BNTX) from Market Perform to Outperform and lowers the price target from $253 to $223.
UBS Says Braze Stock Is A Buy: What Investors Need To Know
UBS initiated coverage on customer engagement platform Braze Inc (NASDAQ: BRZE) on Monday.
What Happened: The analyst firm initiated coverage on Braze with a Buy rating and announced a $53 price target.
Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew
Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ:DYN)…
HC Wainwright Sees Agile Therapeutics’ Twirla Tailwinds Post Roe-Wade Ruling
Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.
EF Hutton Remains Bullish On This Energy Company – Read Why
EF Hutton analyst Ben Piggott reiterated a Buy rating on U.S. Energy Corp (NASDAQ:USEG) and increased the price target to $7 from $6.25…
Analysts Cuts Price Target On MacroGenics – Read Why
BMO Capital Markets downgraded MacroGenics Inc (NASDAQ:MGNX) to Market Perform following the discontinuation of enoblituzumab (B7H3 antibody) for head and neck cancers. The…
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock
BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ:FATE) to Outperform from Market Perform. The analyst believes Fate’s iPSC platform is uniquely positioned…
Read Why EF Hutton Sees Huge Upside In This AgTech Company
EF Hutton analyst Ben Piggott initiated coverage on AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) with a Buy rating and a price target of…